Medical/Pharmaceuticals

Court Sides with Cardiovalve in Edwards patent spat

HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve") against Edwards Lifesciences Corporation and Edwards Lifesciences LLC. ...

2025-08-05 20:00 1713

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight

-          13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overweight. -         All 125 participants enrolled in just over one month; topline data expected in the fourth ...

2025-08-05 18:50 1540

Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors

DONGGUAN, China, Aug 5, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollment  inChina for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tum...

2025-08-05 16:30 1516

WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity

WUXI, China, Aug. 4, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at the Wuxi site has c...

2025-08-05 10:13 1560

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-08-05 08:00 1613

Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First Nanosecond PFA System, Ushering in the PFA 3.0 Era

SHENZHEN, China, Aug. 4, 2025 /PRNewswire/ -- Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovativeNxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval fromChina's National Medical Products Administration (NMPA). ...

2025-08-04 21:30 1838

Vatech Introduces 'Clever One' - A Game-Changing Dental Viewer Solution for the U.S. Market.

FDA-cleared AI dental platform integrates diagnostic support, treatment planning, and patient consultation into one seamless workflow TEANECK, N.J., Aug. 4, 2025 /PRNewswire/ -- Vatech, a global leader in dental imaging innovation, has officially launched 'Vatech® Clever One', its next-generatio...

2025-08-04 21:00 1821

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 3, 2025 /PRNewswire/ -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacr...

2025-08-04 14:29 1191

Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

HONG KONG, Aug. 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by bothChina's National Medical Products Administration (NMPA) and the ...

2025-08-04 13:56 1721

United Imaging Teases Multi-modality "Provider Success" Product Launches at AHRA 2025

The newly FDA-cleared uMR® Ultra and the uOmniscan™ are the first major announcements leading into the AHRA Annual Meeting inLas Vegas. HOUSTON, Aug. 3, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, will again be among the largest exhibitors at ...

2025-08-04 00:22 1726

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance fromChina's Na...

2025-08-01 22:00 3469

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIP...

2025-08-01 20:00 4873

Atombeat and BioDuro Announce Strategic Partnership to Launch an AI-Powered Platform for Accelerated Peptide Drug Discovery

SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, andBioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO),announced a  strategic collaboration to an AI powered platform for accelerated pe...

2025-08-01 18:08 2539

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson's Disease

* The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects. * The results confirmed the favorable safety and tolerability profile of ...

2025-08-01 15:52 2155

Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025

* Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's disease treatments * Engaged in partnering with global big pharma and neurology KOLs, seeking global development collaborations for key products SEOUL, South Korea, July 31,...

2025-07-31 21:00 2231

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

SHENZHEN, China, July 31, 2025 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) ...

2025-07-31 17:55 2419

OMRON Healthcare's Smart Devices Help Detect Early Heart Failure Risks in Over 33% of Study Participants

- Pilot Project on Home-based Heart Failure ICT Monitoring -- Using Vital Data to Enable Early Medical Intervention - KYOTO, Japan, July 31, 2025 /PRNewswire/ -- OMRON Healthcare Co., Ltd., the world's leading manufacturer and distributor of personal heart health products, has successfully concl...

2025-07-31 16:00 1917

Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC

HONG KONG, July 30, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific antibody) in combination with docetaxel for the treatment o...

2025-07-31 09:46 1915

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

BELLEVUE, Wash. and SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today issued a strategic update regarding its recently announced Term Sheet with Woori IO Co., Ltd. ("WORIO"), a South...

2025-07-31 04:10 3775

BON Launches AI-Powered New Drug Research and Development

XI'AN, China, July 30, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D)...

2025-07-30 21:00 2162
1 ... 25262728293031 ... 251